NO20044941L - Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte - Google Patents

Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte

Info

Publication number
NO20044941L
NO20044941L NO20044941A NO20044941A NO20044941L NO 20044941 L NO20044941 L NO 20044941L NO 20044941 A NO20044941 A NO 20044941A NO 20044941 A NO20044941 A NO 20044941A NO 20044941 L NO20044941 L NO 20044941L
Authority
NO
Norway
Prior art keywords
vaccination
virus
relates
neonatal
increase
Prior art date
Application number
NO20044941A
Other languages
English (en)
Other versions
NO336348B1 (no
Inventor
Paul Chaplin
Mark Suter
Mathias Ackermann
Marco Franchini
Sabine Vollstedt
Hans Peter Hefti
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044941(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20044941L publication Critical patent/NO20044941L/no
Publication of NO336348B1 publication Critical patent/NO336348B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår anvendelse av et virus til fremstilling av et legemiddel for vaksinasjon eller behandling av et neonatalt eller prenatalt dyr, inkludert et menneske. Viruset er i stand til å infisere cellene i det neonatale eller prenatale dyr, inkludert menneske, men det er ikke replikerbart. Viruset er fortrinnsvis et Modifisert Vaccinia Virus Ankara. Særlig angår oppfinnelsen vaksinasjon av neonatale mot infeksjoner mot virus som tilhører samme virusgruppe, enn viruset brukt for vaksinasjon. Videre angår oppfinnelsen vaksinasjon av neonatale mot antigener valgt fra fremmede antigener og tumorantigener, hvor tumorantigenet og/eller det fremmede antigen er forskjellig fra antigenet assosiert med viruset. Oppfinnelsen angår videre anvendelse av virus som definert ovenfor for å øke nivået av faktorer som aktiverer dendrittiske celler eller deres forløperceller, og/eller å øke antallet dendrittiske celler eller dets forløperceller og/eller øke produksjonen, og/eller det cellulære innhold av et interferon (IFN) eller IL-12.
NO20044941A 2002-04-19 2004-11-12 Anvendelse av modifisert vacciniavirus Ankara (MCA) til fremstilling av et legemiddel for behandling av et neonatalt dyr. NO336348B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200590 2002-04-19
PCT/EP2003/003994 WO2003088994A2 (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Publications (2)

Publication Number Publication Date
NO20044941L true NO20044941L (no) 2004-11-12
NO336348B1 NO336348B1 (no) 2015-08-03

Family

ID=29225556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044941A NO336348B1 (no) 2002-04-19 2004-11-12 Anvendelse av modifisert vacciniavirus Ankara (MCA) til fremstilling av et legemiddel for behandling av et neonatalt dyr.

Country Status (23)

Country Link
US (3) US7897156B2 (no)
EP (4) EP2204179A3 (no)
JP (4) JP4801880B2 (no)
KR (2) KR101028937B1 (no)
CN (1) CN100540051C (no)
AT (1) ATE366586T2 (no)
AU (1) AU2003239805B2 (no)
BR (1) BR0309339A (no)
CA (1) CA2478009C (no)
CY (1) CY1106848T1 (no)
DE (1) DE60314823T3 (no)
DK (1) DK1420822T4 (no)
EA (1) EA011233B1 (no)
ES (1) ES2288609T5 (no)
IL (1) IL163701A0 (no)
MX (1) MXPA04010353A (no)
NO (1) NO336348B1 (no)
NZ (2) NZ547776A (no)
PL (1) PL220781B1 (no)
PT (1) PT1420822E (no)
SG (1) SG173216A1 (no)
UA (1) UA85371C2 (no)
WO (1) WO2003088994A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
DK1420822T4 (en) * 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
WO2004043490A1 (en) * 2002-11-07 2004-05-27 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Smallpox vaccine regimen
UA100836C2 (ru) 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
EP1835031A1 (en) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
CA2815727C (en) 2010-11-05 2019-09-10 Bavarian Nordic A/S Modulation of immune responses by the poxviral k4 protein
CA2829607A1 (en) 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor
US10973892B2 (en) * 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CN105101993A (zh) * 2013-03-15 2015-11-25 巴法里安诺迪克有限公司 单次高剂量的mva在新生儿和婴儿中诱导保护性免疫反应
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
WO2016144564A2 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US10736962B2 (en) * 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4452305A1 (en) * 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) * 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) * 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU694519B2 (en) * 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
UA68327C2 (en) † 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DE69739372D1 (de) 1996-02-21 2009-06-04 Immunity Kft. Genetic Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
EP0951555A2 (en) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU5091898A (en) * 1996-10-25 1998-05-15 Wistar Institute Of Anatomy And Biology, The Method of vaccinating infants against infections
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
CN1298851C (zh) 1998-11-18 2007-02-07 牛津生物医学（英国）有限公司 多肽
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
RU2280075C2 (ru) * 2000-03-14 2006-07-20 Бавариан Нордик А/С Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
BR0111366A (pt) 2000-05-24 2003-05-20 Merial Sas Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
CA2412050C (en) * 2000-06-15 2011-03-22 Jeffrey Schlom A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
SI21122A (sl) * 2000-07-11 2003-08-31 Bayer Aktiengesellschaft Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CN101676389A (zh) † 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AU2002356690B2 (en) * 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
DK1420822T4 (en) * 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
PL218318B1 (pl) * 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
EP1664661A4 (en) * 2003-09-10 2008-02-13 Ra Brands Llc METHOD OF PRINTING COMPOSITE VENTILATED BAND
WO2005046614A2 (en) * 2003-11-12 2005-05-26 Therion Biologics Corporation System for treating and preventing breast cancer
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Also Published As

Publication number Publication date
UA85371C2 (ru) 2009-01-26
JP2011157400A (ja) 2011-08-18
EA200401405A1 (ru) 2005-04-28
NZ536592A (en) 2007-01-26
SG173216A1 (en) 2011-08-29
JP2010120955A (ja) 2010-06-03
EP2204180A3 (en) 2010-12-22
JP2015061876A (ja) 2015-04-02
KR20110017904A (ko) 2011-02-22
CY1106848T1 (el) 2012-05-23
JP2005523318A (ja) 2005-08-04
DE60314823T2 (de) 2008-03-13
EP1839672A3 (en) 2007-11-21
EP1839672A2 (en) 2007-10-03
KR101028937B1 (ko) 2011-04-12
CN100540051C (zh) 2009-09-16
CA2478009C (en) 2019-03-26
EP1420822A2 (en) 2004-05-26
DK1420822T4 (en) 2017-10-09
US20120183574A1 (en) 2012-07-19
HK1078777A1 (zh) 2006-03-24
US20090104224A1 (en) 2009-04-23
ATE366586T2 (de) 2007-08-15
US8163293B2 (en) 2012-04-24
NO336348B1 (no) 2015-08-03
CN1646158A (zh) 2005-07-27
EP1420822B2 (en) 2017-07-05
DK1420822T3 (da) 2007-10-08
AU2003239805A1 (en) 2003-11-03
EP2204180A2 (en) 2010-07-07
ES2288609T3 (es) 2008-01-16
EP1420822B1 (en) 2007-07-11
JP5690214B2 (ja) 2015-03-25
IL163701A0 (en) 2005-12-18
DE60314823D1 (de) 2007-08-23
EP2204179A3 (en) 2010-12-22
MXPA04010353A (es) 2005-03-07
KR20040111467A (ko) 2004-12-31
AU2003239805B2 (en) 2009-09-10
PL371594A1 (en) 2005-06-27
CA2478009A1 (en) 2003-10-30
BR0309339A (pt) 2005-03-08
WO2003088994A3 (en) 2004-02-19
US7897156B2 (en) 2011-03-01
US20110135683A1 (en) 2011-06-09
NZ547776A (en) 2009-08-28
ES2288609T5 (es) 2017-11-13
EA011233B1 (ru) 2009-02-27
EP2204179A2 (en) 2010-07-07
PL220781B1 (pl) 2016-01-29
WO2003088994A2 (en) 2003-10-30
PT1420822E (pt) 2007-09-04
DE60314823T3 (de) 2017-11-16
JP4801880B2 (ja) 2011-10-26

Similar Documents

Publication Publication Date Title
DK1420822T3 (da) Modificeret vaccinia virus Ankara til vaccination af nyfödte
Todorović-Raković et al. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease
Gherardi et al. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
Mooij et al. Poxvirus MVA expressing SARS-CoV-2 S protein induces robust immunity and protects rhesus macaques from SARS-CoV-2
Barbosa et al. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection
NO20052149L (no) Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
RU2008102654A (ru) Инактивированные химерные вакцины и связанные с ними способы применения
Luan et al. Th2-oriented immune serum after SARS-CoV-2 vaccination does not enhance infection in vitro
Miller et al. Replication-competent recombinant porcine reproductive and respiratory syndrome (PRRS) virus expressing antiviral cytokine interferon-ω5 as a modified live virus vaccine
de Wit et al. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of il-12 or ifn-α/β
TW200509964A (en) VP1 of foot-and-mouth disease virus
Eldi et al. Viral replicative capacity, antigen availability via hematogenous spread, and high TFH: TFR ratios drive induction of potent neutralizing antibody responses
Alhaji Saganuwan Protection of SARS-CoV-2 trial vaccines in human is a function of the viral genomes
Bull et al. Early vaccine‐mediated strain‐specific cytokine imbalance induces mild immunopathology during influenza infection
DE60330795D1 (de) Impfstoff gegen west nile virus
WO2003077859A3 (en) Method of inducing an enhanced immune response against hiv
WO2003076598A3 (en) Method of inducing an enhanced immune response against hiv
Myrzakhmetova et al. Immune reactivity of two biological models to vaccination with inactivated vaccine QazVac against coronavirus infection COVID-19
Lee et al. Effect of apoptosis‐associated speck‐like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant

Legal Events

Date Code Title Description
MK1K Patent expired